In silico study supports the efficacy of a reduced dose regimen for stavudine

Antiviral Research

Volumn 92, Issue 2, 2011, Pages 372-377

  Hurwitz, Selwyn J ^a   Schinazi, Raymond F ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Antiretroviral; D4T; HIV; NONMEM; Nucleosides; Simulation

Indexed keywords

EFAVIRENZ; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; BODY WEIGHT; COMPARATIVE STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; LIPODYSTROPHY; LYMPHOCYTE; METABOLIC DISORDER; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HUMANS; MODELS, STATISTICAL; STAVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80054860864     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.08.004     Document Type: Article

References (49)

1. Ait-Mohand H., Bonmarchand M., Guiguet M., Slama L., Marguet F., Behin A., Amellal B., Bennai Y., Peytavin G., Calvez V., Pialoux G., Murphy R., Katlama C. Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study. HIV Med. 2008, 9:738-746.
2. Balimane P.V., Sinko P.J. Involvement of multiple transporters in the oral absorption of nucleoside analogues. Adv. Drug Deliv. Rev. 1999, 39:183-209.
3. Becher F., Landman R., Mboup S., Kane C.N.T., Canestri A., Liegeois F., Vray M., Prevot M.H., Leleu G., Benech H. Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients. AIDS 2004, 18:181-187.
4. Bygrave H., Ford N., van Cutsem G., Hilderbrand K., Jouquet G., Goemaere E., Vlahakis N., Trivino L., Makakole L., Kranzer K. Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after twoyears. J. Acquir. Immune Defic. Syndr. 2011, 56:e75-78.
5. Casiro' A.D. The Evolving Role of Stavudine as Part of Initial Antiretroviral Therapy in Resource-Constrained Settings. Clinical Care Options 04 2011. <> (accessed 06.03.2011). http://www.clinicaloptions.com.
6. Cournil A., Coudray M., Kouanfack C., Essomba C.N., Tonfack C.A., Biwole-Sida M., Delaporte E., Bork K., Laurent C. Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. Antivir. Ther. 2010, 15:1039-1043.
7. Diamond T.L., Roshal M., Jamburuthugoda V.K., Reynolds H.M., Merriam A.R., Lee K.Y., Balakrishnan M., Bambara R.A., Planelles V., Dewhurst S., Kim B. Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J. Biol. Chem. 2004, 279:51545-51553.
8. Domingo P., Cabeza M.C., Pruvost A., Salazar J., Gutierrez Mdel M., Mateo M.G., Domingo J.C., Fernandez I., Villarroya F., Munoz J., Vidal F., Baiget M. Relationship between HIV/Highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens. Clin. Infect. Dis. 2010, 50:1033-1040.
9. Dube M.P., Komarow L., Mulligan K., Grinspoon S.K., Parker R.A., Robbins G.K., Roubenoff R., Tebas P. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J. Acquir. Immune Defic. Syndr. 2007, 45:508-514.
10. Dube M.P., Parker R.A., Tebas P., Grinspoon S.K., Zackin R.A., Robbins G.K., Roubenoff R., Shafer R.W., Wininger D.A., Meyer W.A., Snyder S.W., Mulligan K. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005, 19:1807-1818.
11. Fromentin E., Asif G., Obikhod A., Hurwitz S.J., Schinazi R.F. Simultaneous quantification of 9-(beta-D-1, 3-dioxolan-4-yl)guanine, Amdoxovir and Zidovudine in human plasma by liquid chromatography-tandem mass spectrometric assay. J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2009, 877:3482-3488.
12. Gallant J.E., Staszewski S., Pozniak A.L., DeJesus E., Suleiman J.M., Miller M.D., Coakley D.F., Lu B., Toole J.J., Cheng A.K. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191-201.
13. Gilead Web site. Enabling access to treatment. Available at: <>, <> (accessed 07.12.2011). http://www.gilead.com/pdf/access_fact_sheet.pdf.
14. Hellerstein M., Hanley M.B., Cesar D., Siler S., Papageorgopoulos C., Wieder E., Schmidt D., Hoh R., Neese R., Macallan D., Deeks S., McCune J.M. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat. Med. 1999, 5:83-89.
15. Hernandez-Santiago B.I., Chen H., Asif G., Beltran T., Mao S., Hurwitz S.J., Grier J., McClure H.M., Chu C.K., Liotta D.C., Schinazi R.F. Pharmacology and pharmacokinetics of the antiviral agent beta-D-2', 3'-dideoxy-3'-oxa-5-fluorocytidine in cells and rhesus monkeys. Antimicrob. Agents Chemother. 2005, 49:2589-2597.
16. Hernandez-Santiago B.I., Mathew J.S., Rapp K.L., Grier J.P., Schinazi R.F. Antiviral and cellular metabolism interactions between dexelvucitabine and lamivudine. Antimicrob. Agents Chemother. 2007, 51:2130-2135.
17. Hernandez-Santiago B.I., Obikhod A., Fromentin E., Hurwitz S.J., Schinazi R.F. Short communication cellular pharmacology of 9-(beta-D-1, 3-dioxolan-4-yl) guanine and its lack of drug interactions with zidovudine in primary human lymphocytes. Antivir Chem Chemother 2007, 18:343-346.
18. Hoffmann C.J., Charalambous S., Fielding K.L., Innes C., Chaisson R.E., Grant A.D., Churchyard G.J. HIV suppression with stavudine 30 mg versus 40 mg in adults over 60kg on antiretroviral therapy in South Africa. AIDS 2009, 23:1784-1786.
19. Horton C.M., Dudley M.N., Kaul S., Mayer K.H., Squires K., Dunkle L., Anderson R. Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Antimicrob. Agents Chemother. 1995, 39:2309-2315.
20. Hurwitz S.J., Asif G., Kivel N.M., Schinazi R.F. Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model. Antimicrob. Agents Chemother. 2008, 52:4241-4250.
21. Hurwitz S.J., Asif G., Schinazi R.F. Development of a population simulation model for HIV monotherapy virological outcomes using lamivudine. Antivir Chem Chemother 2007, 18:329-341.
22. Igoudjil A., Massart J., Begriche K., Descatoire V., Robin M.A., Fromenty B. High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes. Toxicol. In Vitro 2008, 22:887-898.
23. Jacobsson B., Britton S., He Q., Karlsson A., Eriksson S. Decreased thymidine kinase levels in peripheral blood cells from HIV-seropositive individuals: implications for zidovudine metabolism. AIDS Res. Hum. Retroviruses 1995, 11:805-811.
24. Karara M.W., Okalebo F.A., Oluka M.N., Ombega J., Guantai A.N., Osanjo G.O. Comparative tolerability and efficacy of stavudine 30 mg versus stavudine 40 mg in patients on combination antiretroviral therapy in Kenya. Journal of AIDS and HIV Research 2010, 2:24-31.
25. Keiser O., Anastos K., Schechter M., Balestre E., Myer L., Boulle A., Bangsberg D., Toure H., Braitstein P., Sprinz E., Nash D., Hosseinipour M., Dabis F., May M., Brinkhof M.W., Egger M. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Tropical Med. Int. Health 2008, 13:870-879.
26. McComsey, G., Lonergan, J.T., 2004. Mitochondrial dysfunction: patient monitoring and toxicity management. J Acquir Immune Defic Syndr 37 Suppl 1, S30-35.
27. McCutchan J.A. Management of HIV in resource limited settings. Curr Opin Infect Dis 2009, 22:464-470.
28. Mercier S., Gueye N.F., Cournil A., Fontbonne A., Copin N., Ndiaye I., Dupuy A.M., Cames C., Sow P.S., Ndoye I., Delaporte E., Simondon K.B. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study. J. Acquir. Immune Defic. Syndr. 2009, 51:224-230.
29. Mohri H., Perelson A.S., Tung K., Ribeiro R.M., Ramratnam B., Markowitz M., Kost R., Hurley A., Weinberger L., Cesar D., Hellerstein M.K., Ho D.D. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J. Exp. Med. 2001, 194:1277-1287.
30. Panhard X., Legrand M., Taburet A.M., Diquet B., Goujard C., Mentre F. Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. Eur. J. Clin. Pharmacol. 2007, 63:1019-1029.
31. Parikh U.M., Bacheler L., Koontz D., Mellors J.W. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J. Virol. 2006, 80:4971-4977.
32. Pedrol E., Martin T., del Pozo M.A., Flores J., Sanz J., Carton J.A., Jusdado J.J., Arazo P., Ribera E., Deig E. Efficacy and safety of a reduced-dose of stavudine in HIV-infected patients under immunological and virological stable conditions. Med Clin (Barc) 2007, 129:361-365.
33. Plagemann P.G., Wohlhueter R.M., Woffendin C. Nucleoside and nucleobase transport in animal cells. Biochim. Biophys. Acta 1988, 947:405-443.
34. Pujari S.N., Dravid A., Naik E., Bhagat S., Tash K., Nadler J.P., Sinnott J.T. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J. Acquir. Immune Defic. Syndr. 2005, 39:199-202.
35. Rosario M.C., Jacqmin P., Dorr P., van der Ryst E., Hitchcock C. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc. Clin. Pharmacol. Ther. 2005, 78:508-519.
36. Rylova S.N., Albertioni F., Flygh G., Eriksson S. Activity profiles of deoxynucleoside kinases and 5'-nucleotidases in cultured adipocytes and myoblastic cells: insights into mitochondrial toxicity of nucleoside analogs. Biochem. Pharmacol. 2005, 69:951-960.
37. Sanchez-Conde M., de Mendoza C., Jimenez-Nacher I., Barreiro P., Gonzalez-Lahoz J., Soriano V. Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity. HIV Clin Trials 2005, 6:197-202.
38. Schinazi R.F., Hernandez-Santiago B.I., Hurwitz S.J. Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. Antiviral Res. 2006, 71:322-334.
39. Shao, X., 2004. Reverse transcriptase assays of resistance to anti-HIV drugs and their mechanism of action, Ph.D. Thesis, Karolinska Institute, Stockholm, Sweden.
40. Sinxadi P.Z., van der Walt J.S., McIlleron H.M., Badri M., Smith P.J., Dave J.A., Levitt N.S., Maartens G. Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study. AIDS Res Ther 2010, 7:23.
41. Ueno T., Mitsuya H. Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2', 3'-dideoxynucleotide analogs using the single-nucleotide incorporation assay. Biochemistry 1997, 36:1092-1099.
42. van Griensven J., Zachariah R., Rasschaert F., Mugabo J., Atte E.F., Reid T. Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence 2009, timing and risk factors in a three-year cohort in Kigali, Rwanda. Trans R Soc Trop Med Hyg.
43. ViiV Healthcare Web site. Not-for-profit pricing. Available at: < (accessed 07.12.2011). http://www.viivhealthcare.com.
44. Wainberg M.A. Two standards of care for HIV: why are Africans being short-changed?. Retrovirol 2009, 6:109.
45. Walensky R.P., Wood R., Ciaranello A.L., Paltiel A.D., Lorenzana S.B., Anglaret X., Stoler A.W., Freedberg K.A. Scaling up the 2010 World Health Organization HIV treatment guidelines in resource-limited settings: A model-based analysis. PLoS Med. 2010, 7:e1000382.
46. Wendelsdorf K.V., Song Z., Cao Y., Samuels D.C. An analysis of enzyme kinetics data for mitochondrial DNA strand termination by nucleoside reverse transcription inhibitors. PLoS Comput. Biol. 2009, 5:e1000261.
47. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2010 rev. Available at: <> (accessed 05.06.2011). http://www.whqlibdoc.who.int.
48. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2009 website). Available at: <> (accessed July 2011). http://www.who.int/hiv/pub/tuapr_2009_en.pdf.
49. Zhu Z., Ho H.T., Hitchcock M.J., Sommadossi J.P. Cellular pharmacology of 2',3'-didehydro-2',3'-dideoxythymidine (D4T) in human peripheral blood mononuclear cells. Biochem. Pharmacol. 1990, 39:R15-19.